|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Danish Headache Center |
|---|---|
| Information provided by: | Danish Headache Center |
| ClinicalTrials.gov Identifier: | NCT00374530 |
Purpose
Before, during and after intravenous administration of PGE2 we score/measure headache, rCBF, blood flow in the middle cerebral artery and diameter of superficial temporal artery and correlate that to known pathophysiology of headache to see if PGE2 is involved in headache pathophysiology.
| Condition | Intervention |
|---|---|
|
Headache Migraine |
Drug: PGE2 |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Crossover Assignment |
| Official Title: | Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2 |
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | KA-20060026 |
| Study First Received: | September 8, 2006 |
| Last Updated: | July 31, 2007 |
| ClinicalTrials.gov Identifier: | NCT00374530 History of Changes |
| Health Authority: | Denmark: Ethics Committee |
|
Signs and Symptoms Dinoprostone Migraine Disorders Headache Central Nervous System Diseases |
Neurologic Manifestations Headache Disorders, Primary Pain Brain Diseases Headache Disorders |
|
Signs and Symptoms Migraine Disorders Nervous System Diseases Headache Central Nervous System Diseases |
Neurologic Manifestations Headache Disorders, Primary Pain Brain Diseases Headache Disorders |